Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.

Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.
复制标题

DOI:
10.1002/art.30099
复制
发表时间:
2011-01
影响因子:
--
通讯作者:
Escors, David
Escors, David
中科院分区:
其他
文献类型:
--
作者:
Arce, Frederick;Breckpot, Karine;Stephenson, Holly;Karwacz, Katarzyna;Ehrenstein, Michael R.;Collins, Mary;Escors, David

文献摘要

参考文献

被引文献

相似文献

Most therapeutic treatments for autoimmune arthritis rely on immunosuppressive drugs, which have side effects. Although a previous study by our group showed that specific ERK activation suppressed immune responses, its application in a therapeutic setting has never been tested. The aim of the present study was to define the ERK-dependent immunosuppressive mechanisms and to apply selective ERK activation for the treatment of experimental inflammatory arthritis. A constitutively active ERK activator was coexpressed with a model antigen using lentivectors. Immunosuppressive mechanisms were characterized at the level of dendritic cell (DC) function, differentiation of antigen-specific Treg cells, and inhibition of inflammatory T cells. Administration of the ERK activator with antigen as a strategy to suppress inflammatory arthritis was tested in an experimental mouse model. Selective ERK activation induced mouse and human DCs to secrete bioactive transforming growth factor β, a process required for suppression of T cell responses and differentiation of antigen-specific Treg cells. Treg cells strongly proliferated after antigen reencounter in inflammatory conditions, and these cells exhibited antigen-dependent suppressive activities. Inflammatory arthritis was effectively inhibited through antigen-specific mechanisms. Importantly, this strategy did not rely on identification of the initiating arthritogenic antigen. Equivalent mechanisms were demonstrated in human monocyte–derived DCs, setting the scene for a possible rapid translation of this approach to patients with rheumatoid arthritis. This strategy of selective ERK activation resulted in an effective therapeutic protocol, with substantial advantages over DC or T cell vaccination.
DOI: 10.1007/s00005-010-0063-4
发表时间: 2010-04
影响因子: 3.2
作者:
Escors, David;Breckpot, Karine
通讯作者: Breckpot, Karine
DOI: 10.1084/jem.20021598
发表时间: 2002-12-16
影响因子: 15.3
作者:
Bonifaz, L;Bonnyay, D;Mahnke, K;Rivera, M;Nussenzweig, MC;Steinman, RM
通讯作者: Steinman, RM
DOI: 10.1084/jem.194.6.769
发表时间: 2001-09-17
期刊: The Journal of experimental medicine
影响因子: --
作者:
Hawiger D;Inaba K;Dorsett Y;Guo M;Mahnke K;Rivera M;Ravetch JV;Steinman RM;Nussenzweig MC
通讯作者: Nussenzweig MC
DOI: 10.1002/eji.200636704
发表时间: 2007-11-01
影响因子: 5.4
作者:
Hill, Marcelo;Tanguy-Royer, Severine;Anegon, Ignacio
通讯作者: Anegon, Ignacio
DOI: 10.1172/jci27203
发表时间: 2006-04-01
影响因子: 15.9
作者:
Dillon, S;Agrawal, S;Pulendran, B
通讯作者: Pulendran, B